State Street Corp Raises Holdings in Standard BioTools Inc. (NASDAQ:LAB)

State Street Corp raised its holdings in Standard BioTools Inc. (NASDAQ:LAB) by 26.7% in the third quarter, Holdings Channel reports. The fund owned 5,495,136 shares of the company’s stock after buying an additional 1,157,984 shares during the period. State Street Corp’s holdings in Standard BioTools were worth $10,606,000 at the end of the most recent reporting period.

A number of other institutional investors have also recently added to or reduced their stakes in LAB. Arizona State Retirement System increased its position in shares of Standard BioTools by 16.6% during the second quarter. Arizona State Retirement System now owns 69,596 shares of the company’s stock valued at $123,000 after acquiring an additional 9,933 shares during the last quarter. XTX Topco Ltd lifted its position in shares of Standard BioTools by 38.2% during the second quarter. XTX Topco Ltd now owns 35,965 shares of the company’s stock worth $64,000 after purchasing an additional 9,947 shares in the last quarter. Victory Capital Management Inc. boosted its stake in shares of Standard BioTools by 27.3% in the second quarter. Victory Capital Management Inc. now owns 46,967 shares of the company’s stock valued at $83,000 after purchasing an additional 10,067 shares during the period. Nisa Investment Advisors LLC grew its holdings in shares of Standard BioTools by 433.8% in the third quarter. Nisa Investment Advisors LLC now owns 18,128 shares of the company’s stock valued at $35,000 after purchasing an additional 14,732 shares in the last quarter. Finally, Xponance Inc. purchased a new stake in Standard BioTools during the 2nd quarter worth approximately $34,000. Hedge funds and other institutional investors own 53.74% of the company’s stock.

Standard BioTools Price Performance

Shares of NASDAQ LAB opened at $1.90 on Friday. The company has a market cap of $707.29 million, a price-to-earnings ratio of -2.68 and a beta of 1.61. The stock’s 50-day moving average is $1.87 and its two-hundred day moving average is $1.92. Standard BioTools Inc. has a 1-year low of $1.21 and a 1-year high of $3.04.

Analyst Ratings Changes

Separately, TD Cowen decreased their price target on shares of Standard BioTools from $2.75 to $2.50 and set a “buy” rating for the company in a research report on Thursday, October 31st.

About Standard BioTools

Standard BioTools Inc, together with its subsidiaries, provides instruments, consumables, reagents, and software services for researchers and clinical laboratories in the Americas, Europe, the Middle East, Africa, and the Asia pacific. It operates through two segments: Proteomics and Genomics. The company offers analytical systems, such as CyTOF XT System, a CyTOF XT mass cytometry system performs automated high-parameter single-cell analysis using antibodies conjugated to metal isotopes; and Hyperion XTi imaging system, a spatial biology instrument.